Eli Lilly And CO ELI LILLY ORD SHS
Eli Lilly And CO ELI LILLY ORD SH.../ US5324571083 /
0Q1G
23/05/2024 12:30:48
|
Diferencia
-
|
Volumen |
Bid6:00:05 |
Ask6:00:05 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
635.84CHF
|
-
|
13,208 Volumen de negocios: 5,722.56 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
806.07 mil millonesCHF |
- |
- |
Descripción de negocio
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Consejo de gestión & Consejo de supervisión
CEO |
David A. Ricks |
Consejo de gestión |
Anat Ashkenazi, Eric Dozier, Anat Hakim, Edgardo Hernandez, Patrik Jonsson, Michael B. Mason, Johna L. Norton, Diogo Rau, Daniel M. Skovronsky, Jacob Van Naarden, Alonzo Weems, Anne E. White, Ilya Yuffa |
Consejo de supervisión |
David A. Ricks, Ralph Alvarez, Katherine Baicker, J. Erik Fyrwald, Mary Lynne Hedley, Jamere Jackson, Kimberly H. Johnson, William G. Kaelin Jr., Juan R. Luciano, Marschall S. Runge, Gabrielle Sulzberger, Karen Walker |
Datos de la empresa
Nombre: |
Eli Lilly & Company |
Dirección: |
Lilly Corporate Center,Indianapolis, Indiana 46285, USA |
Teléfono: |
+1-317-276-2000 |
Fax: |
+1-317-277-6579 |
E-mail: |
-
|
Internet: |
www.lilly.com |
Industria: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Subsector: |
Pharmaceuticals |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
69.30% |
Fecha de OPI: |
09/07/1970 |
Relación con inversores
Nombre: |
Joe Fletcher |
IR teléfono: |
+1-317-296-2884 |
IR-fax: |
- |
IR e-mail: |
jfletcher@lilly.com
|
Calendario de la empresa
CW 32 | 08/08/2024
Interim Report 2nd Quarter/6 Months
|
CW 44 | 30/10/2024
Interim Report 3rd Quarter/9 Months
|